Steven R. Smith, MD, AdventHealth’s chief scientific officer discussed AdventHealth Translational Research Institute’s decade of discovery in Central Florida on a recent webinar with the Florida Medical Association. “I’ve never been more optimistic about the state of biomedical science and medical science than I am right now,” Smith said.
Smith, who has overseen TRI since its inception, explained the medical research currently taking place, and where the Translational Research Institute (TRI), is headed. “We feel an obligation to conduct research. We want to learn from our patients so we can improve the care we provide them,” Smith said.
TRI’s mission is to extend and improve the quality of lives by conducting world-class, innovative translational research that leads to discoveries and ultimately cures for obesity, diabetes and cardiovascular diseases. Over the past 10 years, TRI researchers have conducted more than 200 studies and produced more than 350 peer reviewed, published works that have helped to advance medicine. Smith explained, “To define it simply, translation is bedside to bench. We’re going to study human biology with cells, tissue and DNA and then we’re going to relate that back to the human condition.”
During the conversation, Smith spoke about the importance of collaboration and innovation in research and answered questions from viewers.
You can watch the webinar by clicking play below:
Before the webinar, FMA invited Smith to talk about why TRI is unique, its milestones and what excited him most about the work being done there. Click here to read that article.